Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

EVA Pharma

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

- PMLiVE

Janssen backs NHS diabetes challenge

Will provide £200,000 to spread innovation across UK

- PMLiVE

Novo Nordisk’s Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

EU flag

Lantus faces first biosimilar rival in Europe

Sanofi prepares for insulin challenge from Boehringer and Lilly

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Sanofi launches diabetes gaming app for children

Mission T1D aims to encourage discussion about how to live with the condition

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links